Glucose deprivation attenuates the anti-tumor immune response triggered by Cytotoxic T Lymphocytes (CTLs) in glycolytic-dependent tumor cells, whereas checkpoint antagonists, such as anti-PD1 or anti PDL1 antibodies, provide glucose to CTLs by inhibiting glycolysis (46, 47). The gene discussed is PDCD1; the disease is neoplasm.